Antiviral Treatment for COVID-19: A Systematic Review

Francisco A. Arias¹², Pier Teran-Chavez¹², Alessandra Maggi-Panato¹², Diego Flores-Ortega¹² and Alex Rojas-Ortega¹²*

¹Escuela de Medicina, Universidad Peruana de Ciencias Aplicadas, Lima, Perú.
²Sociedad Científica de Estudiantes de Medicina de la Universidad Peruana de Ciencia Aplicadas (SOCIEMUPC), Lima, Perú.

Authors’ contributions

This work was carried out in collaboration among all authors. Author FAA designed the study. Author PTC performed the statistical analysis. Authors FAA and PTC wrote the protocol and wrote the first draft of the manuscript. Author ARO managed the literature searches. Authors AMP and DFO individually extracted each of the selected articles and wrote the results. All authors read and approved the final manuscript.

ABSTRACT

Aim: In December 2019, there were reports of a new type of coronavirus that affects the different health systems of the world. We have carried out a systematic review of the possible antivirals studied that could be useful in this public health catastrophe.

Data Sources: A search strategy with MESH terms was performed in PubMed, Web of Science, and Scopus. Also, RCTs published in clinicaltrials.gov were reviewed. The databases were searched between April and June 2020.

Study Selection: We selected all Randomized Controlled Trials evaluating the effects of antivirals and 5 studies were included from a research database of 280 articles collected between. After removing duplicated articles, 43 were selected for review. Finally, 5 articles were eligible for full-text review and included in the article.

*Corresponding author: E-mail: rojasortega04@hotmail.com;
Results: Current randomized controlled trial data showed no clinical improvement in terms of mortality, need for oxygen support or need for intubation in patients who used antivirals versus those who did not. No clinical improvement was demonstrated. It was observed that there is difficulty in calculating clinical improvement, this large difference makes the eligible studies difficult to compare.

Conclusion: These predictors, however, need further work to validate reliability. More clinical trials involving antivirals are needed to observe a relationship between clinical improvement or mortality from SARS-CoV-19.

Keywords: Systematic review; COVID-19; treatment; clinical improvement; mortality.

ABBREVIATIONS

AHF : Acute Heart Failure
AKI : Acute kidney injury
ALT : Alanine Aminotransferase
AMOX-CLAV : Amoxicillin-clavulanate
CHD : Coronary heart disease
CID : Disseminated Intravascular Coagulation
CVA : Cerebrovascular disease
DM : Diabetes Mellitus
HT : Hypertension
ICU : Intensive Care Unit.
LVX : Levofloxacin
MA : Meta-analysis
N-RA : Meta-Regression
PTX : Pneumothorax
RCT : Randomized Controlled Trial
SR : Systematic Review
TZP : Tazobactam-Piperacillin

1. INTRODUCTION

In early December 2019, we received reports of pneumonia cases caused by a new virus in Wuhan, China, taking only 3 months to spread worldwide. Since then, this pandemic has affected health systems worldwide to varying degrees. The World Health Organization (WHO) named this new condition as coronavirus-19 (Covid-19) disease caused by SARS-CoV-2. This new virus, belonging to the extensive family of coronaviruses, already had a history of a previous presentation about severe acute respiratory syndrome (SARS) in 2003 also in China [1].

The fatal case index (CFR) is one of the important measures of impact during outbreaks, epidemics, or pandemics, it is defined as "the proportion of cases of a specified condition that are fatal within a specified time" [2]. What has been reported in studies of SARS-CoV-2 infection in China so far exhibit an approximate CFR of 4.0% [3,4]. In addition to the need for properly equipped intensive care units and their high contagion capacity, the search for an accurate and efficient treatment became a priority in the scientific community.

When the first patient arrived in the United States, experts recommended Remdesivir treatment, and its application was even approved by the Food and Drug Administration (FDA). But the lack of information that will prove its efficacy and validity in the use of Covid-19 cases was quickly questioned [4,5].

In 2003, one trial of Lopinavir-ritonavir and Ribavirin demonstrated reduced mortality and lesser complications in patients with SARS-CoV-1; for this reason, researchers are performing these medications in context on Covid-19 pandemic [6].

In the meantime, several studies have just appeared, and suggest treatments with former results for other viral diseases; but what we do not have is plenty of clinical evidence to apply these for patients with SARS-CoV-2. Besides Remdesivir, Lopinavir-ritonavir, Chloroquine and Hydroxychloroquine, Favipiravir, Umifenovir, Ribavirin, and Interferon have been proven in a sort of trials [7-13].

The main reason for this systematic review is to organize the recent data from COVID-19 and to compare the available antiviral therapies used in this new disease.

2. METHODS

2.1 Search Strategy

A systematic review of RCT’s evaluating the effect of antiviral medications (remdesivir, oseltamivir, favipiravir, lopinavir, ritonavir) was performed. A search strategy with MESH terms was performed in PubMed, Web of Science, and Scopus. Also, RCTs published in clinicaltrials.gov
were reviewed. The databases were searched between April and June 2020. The search strategy was done using the following MESH terms: Coronavirus 2019 OR COVID 19 OR 2019-nCov OR SARS COV-2 OR nCOV disease OR COVID19 OR coronavirus disease 2019 OR novel coronavirus) AND (Antiviral OR treatment OR (Lopinavir AND Ritonavir) OR Umifenovir OR Remdesivir OR Oseltamivir OR Favipiravir OR Ribavirin AND Mortality AND Adverse effects. There were no limitations in language and the time of publication was limited from 2019 to the moment when the search was performed. The search strategy is available in the appendix.

2.2 Study Selection

We Selected all RCT’s evaluating the effects of antivirals (Remdesivir, Oseltamivir, favipiravir, Lopinavir, ritonavir,) on mortality, rate of the need of mechanical ventilation, acute coronary syndrome, and harmful events in patients with a severe or moderate case of COVID. We included studies in any language or with any sample size. We excluded case reports, reviews, editorials, letters to editors, and retrospective studies. Abstracts from all engines were centrally collected in myendnoteweb.com, and duplicates were removed. The selection of abstracts was done independently by two investigators and any discrepancies were solved with a third investigator.

2.3 Data Extraction

Two investigators independently extracted the information from full texts of selected studies, and any discrepancies were solved by a third investigator. Extracted information included the year of publication, length of the study, place where the study was taken, trial phase, the population included, intervention drug, control, trial therapy, and time of follow-up. Also, data from the outcomes were extracted.

2.4 Outcomes

The main outcome considered in the study was mortality, while the secondary outcomes were clinical improvement as defined by the NEWS-2 score, severe respiratory failure (defined by the requirement of mechanical ventilation), the presence of Disseminated Intravascular Coagulation (defined by the increment of levels of D dimer and systemic organ failure) and Acute Heart Failure (defined by acute heart symptoms of fluid overload, acute pulmonary edema and/or left ventricular ejection fraction <40%). Finally, the most common side effects in studies are presented (ALT increase, Lymphopenia, Thrombocytopenia, Rash, Acute Kidney Injury, and Pneumothorax). All the definitions will be described in Table 2.

2.5 Risk of Bias Assessment

Two investigators evaluated the risk of bias of each eligible RCT using the Cochrane collaboration tool for assessing the risk of bias for randomized clinical trials [14]. Any discrepancies were solved by a third investigator. The following criteria were included in the evaluation: Randomness of Allocation sequence, Concealment of Allocation sequence, Blinding of the patient, the investigator and of the outcome, selective reporting, incomplete outcome, and any other biases. Each item was described for each study as Low, high or uncertain risk of bias.

2.6 Additional Analyses

A meta-analysis could not be performed due to the heterogeneity of the included studies. (Fig 3)

3. RESULTS AND DISCUSSION

3.1 Results

3.1.1 Selection of trials

We identified a total of 280 articles in the search engines specified. After removing duplicates, 43 articles left. These were screened by title and abstract, where 36 articles were excluded. Finally, a full-text review was taken for eligibility in 7 articles, where 2 of them were excluded due to not including the outcomes searched in this study (Fig 1). The characteristics of the 5 studies included in this review are shown in Table 1.

3.1.2 Description of trials

Overall baseline characteristics are presented in Table 1. The largest study population was presented by Beigel et al where a total of 1063 participants were considered in the analysis, while the smallest population included was by Hung et al with 127 patients [12,13]. Baseline characteristics show that the highest average age comes from the study by Wang et al with a median age of 66 and an IQR: 57-73, while the predominant gender in almost all studies was male, the only exception being the arbidol-treated group in the trial developed by Chen et al which showed 57.5% of the female population
Diabetes [(30.6%) Beigel et al.], hypertension [(46%) Beigel et al.], cerebrovascular disease [(8%) Cao et al.], and coronary heart disease [(12%) Hung et al.] were the most frequent comorbidities [9,12,13]. Patients in clinical trials by Wang et al. and Hung et al. received basal treatments before conducting the trial [15]. The longest follow-up was 28 days by Wang et al. while the shortest was 10 days by Beigel et al. and Chen et al. [7,11,13].

3.1.3 Risk of bias assessment

In selection bias, the generation of both random sequence and allocation concealment showed a low risk of bias in all 5 selected articles. However, Cao et al., Chen et al. and Hung et al. (60%) presented a high risk of bias in the assessment of performance, blinding of participants and personnel because of their nature as open-label studies [7,9,12]. In the setting of detection bias, Cao et al., Chen et al. and Hung et al. presented a high risk of detection bias due to lack of assessors blinding; while Beigel et al. and Wang et al. showed an unclear risk of bias since this information was not specified [7,9,11,13]. All articles presented a low risk of bias in reporting and attrition. Finally, only Beigel et al. showed a high risk of bias in the 'other' category because that study was sponsored by the pharmaceutical company producing Remdesivir [16] (Fig. 2).

Fig. 1. Flowchart of included studies
### Table 1. Clinical characteristics of the patients at baseline

|                        | Chen C, et al. (N=236) | Cao B, et al. (N=199) | Wang Y, et al. (N=237) | Hung I, et al. (N=127) | Beigel JH, et al. (N=1063) |
|------------------------|------------------------|-----------------------|------------------------|------------------------|---------------------------|
| **Favipiravir**         |                        |                       |                        |                        |                           |
| **Arbidol**            |                        |                       |                        |                        |                           |
| **Lopinavir–ritonavir**|                        |                       |                        |                        |                           |
| **Control**            |                        |                       |                        |                        |                           |
| **Remdesivir**         |                        |                       |                        |                        |                           |
| **Placebo**            |                        |                       |                        |                        |                           |
| **Interferon beta-1b, lopinavir–ritonavir, and ribavirin** |                        |                       |                        |                        |                           |
| **Lopinavir–ritonavir**|                        |                       |                        |                        |                           |
| **Remdesivir (EV)**    |                        |                       |                        |                        |                           |
| **Placebo**            |                        |                       |                        |                        |                           |
| **Mean age (years)**   | 49.1 (50-68)           | 38.4 (48-68)          | 41 (57-73)             | 44 (53-70)             | 49 (31-61)                 |
| **Women (%)**          | 58 (12)                | 13 (10.8)             | 10 (10.1)              | 13 (13)                | 6 (15)                    |
| **Comorbidities**      |                        |                       |                        |                        |                           |
| **DM (%)**             | 14 (12)                | 13 (10.1)             | 40 (25)                | 11 (13)                | 144 (30.6)                |
| **HT (%)**             | 136 (31)               | 30 (25)               | 72 (46)                | 23 (27)                | 231 (49.3)                |
| **CVA (%)**            | 5 (5.1)                | 8 (8)                 | 1 (1)                  | 1 (1)                  | 6 (15)                    |
| **CHD (%)**            | 15 (9)                 | 2 (3)                 | 5 (8.0)                | 5 (12)                 |                           |
| **Treatments received before enrolment no. of patients (%)** |                        |                       |                        |                        |                           |
| **Antibiotic**         | 121 (77)               | 63 (81)               | 44 (51)                | 25 (61)                |                           |
| **AMOX-CLAV**          | 29 (34)                |                       | 4 (10)                 |                       |                           |
| **Azithromycin**       | 7 (8)                  |                       | 8 (20)                 |                       |                           |
| **Ceftriaxone**        | 12 (14)                |                       | 8 (20)                 |                       |                           |
| **Doxycycline**        | 13 (15)                |                       | 8 (20)                 |                       |                           |
| **TZP**                | 5 (6)                  |                       | 11 (13)                | 3 (7)                  |                           |
| **LVX**                | 60 (38)                | 31 (40)               | 6 (7)                  | 2 (5)                  |                           |
| **Corticosteroids therapy** | 29 (18)               | 15 (19)               |                       |                       |                           |
| **Interferon alfa-2b** | 27 (17)                |                       |                       |                       |                           |
| **Lopinavir–ritonavir**| 25 (15.8)              |                       |                       |                       |                           |
| **Vaspressors**        | 1600 mg 2/first 200 mg day followed by 600 mg 2/day | 400 mg-100 mg/day | 200 mg on day 1 followed by 100 mg on days 2–10 in single daily infusions | Remdesivir 400 mg and ribavirin 400 mg every 12 h, and three doses of 8 million international units of interferon beta-1b on alternate days | 200-mg loading dose on day 1, followed by a 100-mg maintenance dose administered daily on days 2 through 10 or until hospital discharge or death. |
**Table 2. Clinical outcomes of included studies**

| Region                        | Favipiravir | Arbidol | Lopinavir–Ritonavir | Control | Remdesivir | Placebo | Interferon beta-1b, lopinavir–ritonavir, and ribavirin | Lopinavir–Ritonavir | Remdesivir (EV) | Placebo | Hospital stay. Median. days (IQR) | Clinical Improvement DAY 7 no. (%) | Difference Improvement † | Score on seven-category scale at day 7 — no. of patients (%) |
|-------------------------------|-------------|---------|---------------------|---------|------------|---------|----------------------------------------------------|---------------------|----------------|---------|-----------------------------------|---------------------------|-----------------------------|--------------------------------|
| China (N=120)                 | 15 (12-17)  | 14 (12-17)| 16 (13-18)         | 25 (17-37)| 25 (16-36) | 24 (18-36) | 9 (7 to 13)                                       | 14.5 (9.3-16)       |                |         | 6 (6.1)                           | 2 (2)                     | 4.1 (-1.4 to 9.5)           | 0 (-4.3 to 4.2)               |
| China (N=116)                 |             |         |                     |         |            |         |                                                   |                     |                |         |                                   |                           | 4 (4)                      |                                 |
| China (N=100)                 |             |         |                     |         |            |         |                                                   |                     |                |         | 6 (6.1)                           | 2 (2)                     | 4 (3)                       |                                 |
| China (N=158)                 |             |         |                     |         |            |         |                                                   |                     |                |         |                                   |                           | 4 (3)                       |                                 |
| China (N=79)                  |             |         |                     |         |            |         |                                                   |                     |                |         |                                   |                           | 2 (3)                       |                                 |
| China (N=86)                  |             |         |                     |         |            |         |                                                   |                     |                |         |                                   |                           | 2 (3)                       |                                 |
| China (N=41)                  |             |         |                     |         |            |         |                                                   |                     |                |         |                                   |                           | 2 (3)                       |                                 |
| United States, Denmark, UK, Greece, Germany, Korea, Mexico, Spain, Japan, Singapore (N=541) |             |         |                     |         |            |         |                                                   |                     |                |         |                                   |                           | 2 (3)                       |                                 |
| China (N=522)                 |             |         |                     |         |            |         |                                                   |                     |                |         |                                   |                           | 2 (3)                       |                                 |

**Outcomes**
- Follow-up (days)
- Median time hospitalized*
- Median time hospitalized* 14(12-17) 16(13-18) 25(16-38) 24(18-36) 9 (7–13) 14(9.3–16) 9 (6–12) 9 (7–13)
- Follow-up (days) 10 14 28 14 10
- Outcomes
  - Clinical Improvement, Mortality, Severe Respiratory Failure, Cid, AHF, Lymphopenia, Thrombocytopenia, Increase ALT, Rash, AKI
  - Clinical Improvement, Mortality, Severe Respiratory Failure, Cid, AHF, Thrombocytopenia, Increase ALT, Rash and AKI
  - Clinical Improvement and mortality

**Note:**
- Numerical variables were presented with IQR (interquartile range).
- AHF: Acute Heart Failure
- AKI: Acute kidney injury
- ALT: Alanine Aminotransferase
- AMOX–CLAV: Amoxicillin–clavulanate
- CHD: Coronary heart disease
- CID: Disseminated Intravascular Coagulation
- CVA: Cerebrovascular disease
- DM: Diabetes Mellitus
- HT: Hypertension
- ICU: Intensive Care Unit
- PTX: Pneumothorax
- LVX: Levofloxacin
- TZP: Tazobactam–Piperacillin

---

*Chen C, et al* (N=236)
*Cao B, et al* (N=199)
*Wang Y, et al* (N=237)
*Hung I, et al* (N=127)
*Beigel JH, et al* (N=1063)
Hospitalization, requiring ECMO, invasive mechanical ventilation, or both | 6 (6.1) | 4 (4) | 6 (4) | 4 (5)  
---|---|---|---|---
Death | 5 (5.1) | 7 (7) | 10 (6) | 4 (5)  
Clinical Improvement DAY 14 no. (%) | 45 (45.5) | 30 (30) | 42 (27) | 19 (23)  
Difference Improvement † | 15.5 (2.2 to 28.8) | 3.5 (–8.1 to 15.1)  
**Score on seven-category scale at day 14 — no. of patients (%)** | | | |  
Not hospitalized, but unable to resume normal activities | 43 (43.4) | 28 (28) | 39 (25) | 18 (23)  
Hospitalization, not requiring supplemental oxygen | 8 (8.1) | 24 (24) | 21 (14) | 10 (13)  
Hospitalization, requiring supplemental oxygen | 25 (25.3) | 20 (20) | 61 (40) | 28 (36)  
Hospitalization, requiring HFNC or noninvasive mechanical ventilation | 5 (5.1) | 6 (6) | 13 (8) | 8 (10)  
Hospitalization, requiring ECMO, invasive mechanical ventilation, or both | 3 (3) | 5 (5) | 4 (3) | 7 (9)  
Death | 15 (15.2) | 17 (17) | 15 (10) | 7 (9)  
Clinical Improvement DAY 28 no. (%) | 78 (78.8) | 70 (70) | 103 (65) | 45 (58)  
Difference Improvement † | 8.8 (–3.3 to 20.9) | 7.5 (–5.7 to 20.7)  
**Score on seven-category scale at day 28 — no. of patients (%)** | | | |  
Not hospitalized, but unable to resume normal activities | 92 (61) | 45 (58)  
Hospitalization, not requiring supplemental oxygen | 14 (9) | 4 (5)  
Hospitalization, requiring supplemental oxygen | 18 (12) | 13 (1)  
Hospitalization, requiring HFNC or noninvasive mechanical ventilation | 2 (1) | 2 (3)  
Hospitalization, requiring ECMO, invasive mechanical ventilation, or both | 2 (1) | 3 (4)  
Death | 22 (15) | 10 (13)
|                                | 0      | 0      | 19 (19.2) | 25 (25.0) | 22 (15) | 10 (13) | 0      | 0      | 32      | 54      |
|--------------------------------|--------|--------|-----------|-----------|---------|---------|--------|--------|---------|---------|
| Entering ICU no. of patients (%)| 2 (1.72)| 2 (1.67) |           |           |         |         |        |        |         |         |
| Severe Respiratory Failure - Intubation (no. of days and DS) | 5 (3-9) | 8 (5-17) |           |           |         |         |        |        |         |         |
| CID no. of patients (%)        | 1 (1.1) | 1 (1)   | 1 (1)     | 1 (1)     |         |         |        |        |         |         |
| AHF no. of patients (%)        | 0      | 1 (1)   | 8 (5)     | 7 (9)     |         |         |        |        |         |         |
| Adverse Events no. of patients (%) |       |         |           |           |         |         |        |        |         |         |
| Lymphopenia                    | 16 (16.8) | 12 (12.1) |           |           |         |         |        |        |         |         |
| Thrombocytopenia               | 6 (6.5) | 10 (10.1) |           |           |         |         |        |        |         |         |
| Increase ALT                   | 9 (7)° | 12 (10)° | 1 (1.1)   | 4 (4)     | 2 (1)   | 0       | 11 (13) | 7 (17) |         |         |
| Rash                           | 2 (2.1) | 0       | 11 (7)    | 2 (3)     |         |         |        |        |         |         |
| AKI                            | 3 (3.2) | 6 (6.1) | 1 (1)     |           |         |         |        |        |         |         |
| PTX                            | 0      | 0       |           |           |         |         |        |        |         |         |

AKI: Acute kidney injury ALT: Alanine Aminotransferase AST: Aspartate Aminotransferase CID: Disseminated Intravascular Coagulation ICU denotes intensive care unit. PTX: Pneumothorax

† Differences were expressed as rate differences or median differences and 95% confidence intervals.
§ Beigle JH, et al, presents the following data divided into 3 different categories, which comprise the following classification: 1, not hospitalized, no limitations of activities; 2, not hospitalized, limitation of activities, home oxygen requirement, or both; 3, hospitalized, not requiring supplemental oxygen and no longer requiring ongoing medical care (used if hospitalization was extended for infection-control reasons)

* Beigle HJ, et al presents the data of the score on day 15 (± 2 days) - no. of patients (%)

° ALT and/or AST were elevated
Fig. 2. Risk of bias table. Legend: Red (-) = high risk of bias; Yellow (?) = unknown risk of bias; Green (+) = low risk of bias

Fig. 3. Forest plot of included studies
3.1.4 Main findings

3.1.4.1 Mortality

In the randomized clinical trials (RTC’s) analyzed, it was evidenced that the drugs used did not associate improvement in mortality in patients with COVID-19 compared to standard care, the need for invasive ventilation, hospitalization without oxygen, hospitalization with oxygen or non-invasive ventilation, or treatment discontinuation [9,11]. Besides, the highest mortality of RCTs was from Beigel et al. (54%) in the control group compared to the rest of the trials, however, this also presented the largest study population (1063) from different nationalities, indicating that it included a larger and diverse population [13].

3.1.4.2 Clinical improvement

The studies that include the evaluation of clinical improvement as outcomes (Cao et al., Wang et al.) showed most patients that required hospitalization by day 14 were in the control subgroup, in comparison with the patients in the Lopinavir-Ritonavir subgroup [9,11]. Patients requiring Extracorporeal membrane oxygenation (ECMO) or mechanical ventilation were predominant in the control subgroup versus the patients receiving Remdesivir. There were no other major differences in the results reported. Remdesivir recently had proved better clinical outcomes in a phase 3 trial.

3.1.4.3 Severe Respiratory Failure, DIC, and AHF

One of the most outstanding results among secondary outcomes was the need for intubation due to severe respiratory failure, whose data were presented by Cao et al. and Wang et al. [9,11] They provide data on the number of days of intubation, and in addition to the IQR (Cao et al. 5 days, IQR: 3-9 and Wang et al. 8 days, IQR: 5-17); Regarding the trial developed by Wang et al, there was no significant difference between the different study groups, the following data being found in the group treated with remdesivir presented a median of 7 days with an IQR: 3-13.5; while the placebo group had a median of 16 days with an IQR: 8-21. [7,11] Regarding the presence of acute heart failure (ACF) Cao et al. it only showed 1% with this affection in the control group, Wang et al. presented 5% of cases of acute heart failure in the treatment group, and 9% of cases of acute heart failure in the placebo group. [9,11] Finally, disseminated intravascular coagulation (DIC) occurred only in the trial developed by Cao et al., Showing no significant difference between the analyzed groups [9].

3.1.4.4 Side effects of medications

In the set of side effects observed in the articles included in this systematic review, we considered 6 of them as the most relevant. Five of the six articles included presented these side effects. Beigel et al. does not present any side effects in their population [13]. The increase of ALT (Alanine aminotransferase) is the side effect more commonly presented. Hung et al. showed the highest prevalence of increased ALT in their population. Despite this information, it is known that patients without antiviral treatment raise ALT and AST levels [12,16]. The treatment group (Interferon-beta-1b, lopinavir-ritonavir, and ribavirin group with 13%; and Lopinavir-ritonavir alone group with 17%). The lowest prevalence of increased ALT was presented by Wang et al. with 1% in the treatment group, and 0% in the placebo group [11]. The rash, acute kidney injury and thrombocytopenia were showed by Cao et al. and Wang et al. [9,11] In their treatment group, Wang et al. presented the highest prevalence of thrombocytopenia (10% versus 6.3% in the treatment group of Cao et al.) [9,11]. The rash was highest in the treatment group of Wang et al. with 7%, and the acute kidney injury was highest in prevalence in the control group of Cao et al. study (6.1% versus 3.2% of the treatment group) [9,11].

3.2 Discussion

3.2.1 What we know from the literature

Recently, FDA approved Remdesivir as a drug available for the treatment of COVID-19 [17]. Piscoya et al. demonstrated in a systematic review that Remdesivir had a significantly shorter time to recover from symptoms, and fewer adverse events than placebo groups; however, it does not reduce the all-cause mortality outcome [18]. Moreover, Musa et al concluded that there is limited evidence supporting that Remdesivir might be effective to treat COVID either in vitro or in vivo, so the use of this drug should be delayed until high-quality phase 3 RCT’s studying it are completed. Its therapeutic potential is still to be determined [16,15,19].

On the other hand, Youseffard et al. showed that Lopinavir-Ritonavir was ineffective in improving the patient’s outcomes. While Zhang et al. in their SR, MA, and N-RA, did not found any
superiority of Lopinavir-Ritonavir when compared with other antivirals. But they found a relationship with the use of corticosteroids and the development of ARDS [20,21]. Several studies have been proposing different treatments in this context of the SARS-CoV-2 pandemic. For example, Chowdhury et al found that both chloroquine and hydroxychloroquine showed favorable outcomes in the recovery of COVID-19 patients. This was explained since the Viral Load was significantly reduced in the patients using this therapeutic. Also, they concluded that further research is required [22].

Another advance found was made by Cortegiani et al. presented in vitro evidence of chloroquine, showing its efficacy in reducing viral replication and its changes in the cell’s pH level. However, unpublished clinical evidence is not robust to the recommendations; and the need for prior examinations before medication makes access difficult to use [23].

Heidary et al. found that even though Ivermectin is an effective antiviral agent in vitro, its effect has not been reproduced in living mice models with a different virus. Also, the antiviral activity of this drug is being noted while using concentrations around 1ugram/ml, the doses used in humans is way lower in the range of 20-80ng/ml [24].

Additionally, Liu et al. found in their SR and metanalyses that there was insufficient evidence that suggests any benefit from the treatments included (Lopinavir/Ritonavir, Ribavirin, Chloroquine, hydroxychloroquine, arbidol, favipiravir) in the clinical outcomes of the patients. Also, they found an increase in the GI adverse events with the use of Lopinavir/ritonavir [18].

Di Lorenzo et al. and Youseffard et al. concluded in their systematic reviews, that there is an urgent need for phase 3 RCT’s to be completed and published, to find better associations between the clinical outcomes and the medications used [20,25].

Finally, it is well known that patients with SARS-CoV-2 with only supportive care presents some degree of liver damage, with a rise in AST and ALT levels, with no clinical manifestations [17].

3.2.2 What’s new on our study

This study adds Clinical improvement as an outcome using the NEWS-2 Score, which was not included in previous systematic reviews. Also, this paper includes the evaluation of specific side effects of the antivirals; and besides, it includes the evaluation of some of the complications commonly associated with COVID-19. These outcomes were not included in most of the previously published systematic reviews. In this systematic review, the latest updates in clinical improvement of patients focused only on antivirals are studied.

4. LIMITATIONS

The main limitation of this study is that the data included was recollected from other studies. Furthermore, only a limited number of eligible published RCTs on the subject could be chosen, which did not have validation. Most of them also have a very small population included. Another limitation is the population from the studies are different from each other, and not all of them consider the same outcomes for their RCTs.

5. CONCLUSION

It is important to consider that the use of the antivirals mentioned in the study may cause certain adverse effects. Among them, the elevation of alanine aminotransferase was evident in all antivirals in this systematic review. The use of clinical improvement scales, as in the case of NEWS-2 Score, helps the follow-up of the patients included in the trials and allows us to have quick and understandable reading data. Some more serious side effects like CID and AHF are mentioned in 2 of these studies. Also, other adverse effects are mentioned in studies such as acute kidney damage, thrombocytopenia, among others. More clinical trials involving antivirals are needed to observe a relationship between clinical improvement or mortality from SARS-CoV-19.

DECLARATION

The Authors declare that they have taken extreme care with the handling of data and identity since it is a bibliometric study, no people have been surveyed or their data has been obtained, so we have not violated any normal ethics.

CONSENT

It is not applicable.
ETHICAL APPROVAL

It is not applicable.

ACKNOWLEDGEMENTS

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Stadler K, Masignani V, Eickmann M, et al. SARS−beginning to understand a new virus. Nat Rev Microbiol. 2003;1(3):209-18. DOI: https://doi.org/10.1038/nrmicro775
2. Porta M. A dictionary of epidemiology. 5th ed. Oxford: Oxford University Press; 2008.
3. Yang HY, Duan GC. Zhonghua analysis of the epidemic factors for the Coronavirus disease. 2020;54(0):E021. DOI: 10.3760/cma.j.cn112150-20200227-00196
4. Spychalski P, Błażyńska-Spychalska A, Kobiela J. Estimating case fatality rates of COVID-19. Lancet Infect Dis. 2020;20(7):774-775. DOI: 10.1016/S1473-3099(20)30246-2
5. Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020;382(10):929-936. DOI: 10.1056/NEJMoa2001191
6. Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252-256. DOI: 10.1136/thorax.2003.012658
7. Chen C, Zhang Y, Huang J, et al. Favipiravir versus arbidol for COVID-19: A randomized clinical trial. medRxiv; 2020. DOI: https://doi.org/10.1101/2020.03.17.20037432
8. Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: Results of a randomized clinical trial. medRxiv. (In press); 2020. DOI: https://doi.org/10.1101/2020.03.22.20040758
9. Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020; 382:1787-1799. DOI: 10.1056/NEJMoa2001282
10. Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) Infection A Randomized Clinical Trial. JAMA Network Open. 2020; 3(4):208857. DOI: 10.1001/jamanetworkopen.2020.8857
11. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: A randomized, double-blind, placebo-controlled, multicentre trial. The Lancet. 2020;395(10236):1569-1578. DOI: 10.1016/S0140-6736(20)31022-9
12. Hung IFN, Lung KC, Tso EYK, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: An open-label, randomized, phase 2 trial. The Lancet. 2020;395:1695-1704. DOI: 10.1016/S0140-6736(20)31042-4
13. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - preliminary report. N Engl J Med; 2020. DOI: 10.1056/NEJMoa2007764
14. Higgins JP, Altman DG, Gotzsche PC, et al. The cochrane collaboration's tool for assessing risk of bias in randomized trials. BMJ. 2011;343:d5928. DOI: 10.1136/bmj.d5928
15. Liu W, Zhou P, Chen K, et al. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis. Canadian Medical Association Journal. 2020;192(27):E734-E744. DOI: https://doi.org/10.1503/cmaj.200647
16. Guan GW, Gao L, Wang JW, et al. Exploring the mechanism of liver enzyme abnormalities in patients with Novel Coronavirus-infected pneumonia. Zhonghua Gan Zang Bing Za Zhi. 2020; 28(2):100-106. DOI: 10.3760/cma.j.issn.10073418.2020-02.002
17. U.S. FOOD & DRUG Administration [Internet]. California U.S. Food & Drug Administration. Remdesivir EUA Letter of Authorization. 2020;6. [Accessed 10 July 2020].
18. Piscoya A, Ng-Sueng L, Parra del Riego A, et al. Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis. medRxiv; 2020. DOI: https://doi.org/10.1101/2020.05.26.20109595

19. Musa A, Pendi K, Hashemi A, et al. Remdesivir for the Treatment of COVID-19: A systematic review of the literature. West J Emerg Med. 2020;21(4). DOI: 10.5811/westjem.2020.5.47658

20. Yousefifard M, Zali A, Mohamed Ali K, et al. Antiviral therapy in the management of COVID-19: A systematic review on current evidence. 2020;8(1):45. DOI: https://doi.org/10.1111/jcpc.13557

21. Zhang JJY, Lee KS, Ang LW, Leo YS, Young BE. Risk factors of severe disease and efficacy of treatment in patients infected with COVID-19: A systematic review, meta-analysis, and meta-regression analysis. Clinical Infectious Diseases; 2020. DOI: 10.1093/cid/ciaa576

22. Chowdhury MS, Rathod J, Gernsheimer J. Rapid systematic review of clinical trials utilizing chloroquine and hydroxychloroquine as a Treatment for COVID-19. Acad Emerg Med. 2020;27(6):493-504. DOI: 10.1111/acem.14005

23. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy of chloroquine for the treatment of COVID-19. Crit Care. 2020;57:279-283. DOI: https://doi.org/10.1016/j.jcrc.2020.0-3.005

24. Heidary F, Gharebaghi R. Ivermectin: A systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot; 2020. DOI: https://doi.org/10.1038/s41429-020-0336-z

25. Di Lorenzo G, Di Trolio R, Kozlakidis Z, et al. COVID 19 therapies and anti-cancer drugs: A systematic review of recent literature. Crit Rev Oncol Hematol. 2020;152:102991. DOI: 10.1016/j.critrevonc.2020.102991

© 2020 Arias et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
http://www.sdiarticle4.com/review-history/59476